PMID- 31686827
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 15
DP  - 2019
TI  - Soluble epoxide hydrolase inhibition enhances anti-inflammatory and antioxidative 
      processes, modulates microglia polarization, and promotes recovery after ischemic 
      stroke.
PG  - 2927-2941
LID - 10.2147/NDT.S210403 [doi]
AB  - BACKGROUND: Ischemic stroke triggers inflammatory responses and oxidative stress 
      in the brain, and microglia polarization affects the degree of neuroinflammation. 
      It has been reported that the inhibition of soluble epoxide hydrolase (sEH) 
      activity protects brain tissue. However, the anti-inflammatory and antioxidative 
      effects of sEH inhibition in the ischemic brain are not fully understood. This 
      study aimed to investigate the effects of a selective sEH inhibitor, 
      12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), after ischemic stroke. 
      METHODS: Adult male rats with middle cerebral artery occlusion (MCAO) were 
      administered with AUDA or a vehicle. Behavioral outcome, infarct volume, 
      microglia polarization, and gene expression were assessed. RESULTS: Rats treated 
      with AUDA showed better behavioral outcomes and smaller infarct volumes after 
      MCAO. After AUDA treatment, a reduction of M1 microglia and an increase of M2 
      microglia occurred at the ischemic cortex of rats. Additionally, there was an 
      increase in the mRNA expressions of antioxidant enzymes and anti-inflammatory 
      interleukin-10, and pro-inflammatory mediators were decreased after AUDA 
      administration. Heme oxygenase-1 was mainly expressed by neurons, and AUDA was 
      found to improve the survival of neurons. CONCLUSION: The results of this study 
      provided novel and significant insights into how AUDA can improve outcomes and 
      modulate inflammation and oxidative stress after ischemic stroke.
CI  - (c) 2019 Yeh et al.
FAU - Yeh, Chien-Fu
AU  - Yeh CF
AD  - Institute of Brain Science, National Yang-Ming University, Taipei 11221, Taiwan.
AD  - Department of Otorhinolaryngology, National Yang-Ming University, Taipei 11221, 
      Taiwan.
AD  - Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General 
      Hospital, Taipei 11217, Taiwan.
FAU - Chuang, Tung-Yueh
AU  - Chuang TY
AD  - Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei 
      11217, Taiwan.
FAU - Hung, Yu-Wen
AU  - Hung YW
AD  - Institute of Cellular and System Medicine, National Health Research Institutes, 
      Miaoli County 35053, Taiwan.
FAU - Lan, Ming-Ying
AU  - Lan MY
AD  - Department of Otorhinolaryngology, National Yang-Ming University, Taipei 11221, 
      Taiwan.
AD  - Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General 
      Hospital, Taipei 11217, Taiwan.
FAU - Tsai, Ching-Han
AU  - Tsai CH
AD  - Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei 
      11217, Taiwan.
FAU - Huang, Hao-Xiang
AU  - Huang HX
AD  - Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei 
      11217, Taiwan.
FAU - Lin, Yung-Yang
AU  - Lin YY
AD  - Institute of Brain Science, National Yang-Ming University, Taipei 11221, Taiwan.
AD  - Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei 
      11217, Taiwan.
AD  - Institute of Physiology, National Yang-Ming University, Taipei 11221, Taiwan.
AD  - Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, 
      Taiwan.
AD  - Department of Neurology, Neurological Institute, Taipei Veterans General 
      Hospital, Taipei 11217, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20191015
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC6800549
OTO - NOTNLM
OT  - anti-inflammation
OT  - antioxidant
OT  - ischemic stroke
OT  - microglia polarization
OT  - middle cerebral artery occlusion
OT  - soluble epoxide hydrolase
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/10/15
CRDT- 2019/11/06 06:00
PHST- 2019/03/29 00:00 [received]
PHST- 2019/07/04 00:00 [accepted]
PHST- 2019/11/06 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/10/15 00:00 [pmc-release]
AID - 210403 [pii]
AID - 10.2147/NDT.S210403 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2019 Oct 15;15:2927-2941. doi: 10.2147/NDT.S210403. 
      eCollection 2019.